Duality Biologics
Shanghai · Founded 2020
About Duality Biologics
“To Translate Novel Modality into Reality”. Duality Biologics was founded in January 2020 by Dr. John Zhu, a well-respected investor in the healthcare industry. Duality Bio is committed to developing novel modality drugs to fulfill the unmet medical needs for patients worldwide. Focusing on the oncology and autoimmune diseases, the company has built a novel internal pipeline including nearly 10 Best-in-Class and First-in-Class bispecific antibody and Antibody-Drug Conjugate (ADC) drugs, of which several drug candidates are in the IND stage. The company has successfully built the next-generation ADC platform with global intellectual property rights. The value of this platform has been validated by a number of drug candidates under development.
Company Facts
- Founded: 2020
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $100K – $500K
- Total funding: $90.0M
- Funding stage: IPO
- Last round: Series B (May 2021)
- Ticker: hkg:9606
- Website: https://www.dualitybiologics.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/duality-biologics-97638 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.